Insights: Why Tests Fail

by | May 1, 2020 | Human Clinical Diagnostics

Home » Human Clinical Diagnostics » Insights: Why Tests Fail

LexaGene CEO Dr. Jack Regan featured in Science News email update 24 April 2020.

Here is an excerpt from the newsletter featuring Dr. Regan’s insights:

Q&A: When the Tests Fail

To find out why fast diagnostic tests for COVID-19 sometimes fail, Science News talked to Jack Regan, a virologist who founded LexaGene, a company based in Beverly, Mass., that is developing a test that would detect COVID-19, influenza and other common respiratory viruses at the same time. The interview has been edited for brevity and clarity.

SN: Why does it matter if a small percentage of people get a false negative result?

Regan: There are reports that the Abbot ID NOW test, touted as giving a result in as little as five minutes, has a sensitivity of only about 85 percent. That means if you test 100 people, you’re going to send 15 of them home thinking that they’re not infected when they really are.

That is a big problem … [because] we can’t be sending 15 people home telling them they’re not sick, or sending them to a COVID-19-free ward at the hospital where they could infect other people.

SN: Why do these fast diagnostic tests sometimes give false negatives?

Regan: Everybody wants their cake and ice cream, too. They want very, very high quality data and they want it instantaneously. Because companies are prioritizing speed, they often skip a critical step called sample prep. It’s the process of taking a [nose swab sample, for example,] and purifying the genetic material in it prior to doing an analysis. The reason that’s important is because there are numerous chemicals and compounds in a sample that can inhibit chemical reactions in the tests that are necessary to give an accurate response.

For instance, people who are sick are often on a lot of medications, and chemicals in those medications can inhibit the reactions. Smoking or drinking coffee that day might have something that can inhibit a reaction. So if you skip sample prep, you make yourself more susceptible to getting a false negative.

And genetic material likes to create structures that are more stable. PCR genetic tests, which are considered the gold standard for diagnostic tests but take longer to give a result, use cycles of higher and lower temperature to melt the structures and make the genetic material more accessible. If you’re operating at a single temperature, which many of the rapid tests do, those structures can be harder for a test to unfold and read. This can contribute to the failure of the chemistry.

SN: Are there concerns about diagnostic tests you could do at home?

Regan: Sample collection is key for getting an accurate result. If you ask people to do it themselves, they’re going to stick a nasal swab up just past the nasal opening an inch or inch and a half. In reality, you want to stick that swab in four or five inches and rub the inside of the nasal cavity. It’s really uncomfortable. This requires a lot of training in a health care setting to get right.

<a href="https://lexagene.com/author/lexagene-admin/" target="_self">LexaGene</a>

LexaGene

LexaGene develops fully automated, rapid molecular testing at the point-of-need for accurate pathogen detection in human clinical diagnostics, veterinary diagnostics, food safety, and other markets.

Survey Says Veterinarians Have an Appetite for In-Clinic Diagnostic Technology

This spring LexaGene conducted a market research survey in conjunction with AAHA to assess the opinions of practicing veterinarians on AMR stewardship and the use of antibiotics in the treatment of companion animals.

The Dawn of the Superbugs

The most menacing of all resistant bacteria are the so called “super bugs”- strains of bacteria that are resistant to several different classes of antibiotics or multidrug resistant.

LexaGene offers North Shore Technology Council (NSTC) and Leadership Team at MassBio a tour of our Beverly Facility

Recently, we welcomed members of North Shore Technology Council and MassBio Leadership Teams into our facility at 500 Cummings Center for a full tour of our office space and laboratory spaces.

Upcoming Events

BioFuture

NYC
October 05, 2021 - October 06, 2021
The in-person and virtual event held in New York City attracted more than 550 attendees, including 100 speakers sharing their expertise, insight, and predictions.

Latest Resources

Sorry, we don't have any content in this category with that format. Is there anything we can help you with?